WordNet
- insurance that pays all or part of a patients hospital expense (同)hospitalization
- a period of time when you are confined to a hospital; "now they try to shorten the patients hospitalization"
- the condition of being treated as a patient in a hospital; "he hoped to avoid the expense of hospitalization"
- placing in medical care in a hospital (同)hospitalisation, hospital_care
- promise of reimbursement in the case of loss; paid to people or companies so concerned about hazards that they have made prepayments to an insurance company
PrepTutorEJDIC
- 〈U〉『保険』保険契約 / 〈U〉『保険金』,保険料 / 〈U〉保険業 / 〈C〉(一般に)予防(保護)手段
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Comparative effectiveness of olmesartan and other Angiotensin receptor blockers in diabetes mellitus: retrospective cohort study.
- Padwal R1, Lin M, Etminan M, Eurich DT.Author information 1Clinical Epidemiology, Clinical Pharmacology, and General Internal Medicine, University of Alberta, 5-134 Clinical Sciences Bldg, 11350-83rd Ave, Edmonton, AB T6G2G3, Canada. rpadwal@ualberta.ca.AbstractOlmesartan has been linked with increased risk of cardiovascular mortality and sprue-like enteropathy. We compared outcomes between olmesartan and other angiotensin receptor blockers in a large clinical registry of patients with diabetes mellitus. A retrospective cohort analysis using nationwide US-integrated insurance and laboratory claims was performed in 45 185 incident diabetic angiotensin receptor blocker users, including 10 370 (23%) olmesartan users. Hazard ratios were computed using time-dependant Cox models adjusted for sociodemographic characteristics, comorbidities, laboratory data, drug use, healthcare utilization, and the propensity to receive olmesartan. Blood pressure data were unavailable. Subjects were followed up for 116 721 patient-years. The primary end point was all-cause hospitalization or all-cause mortality and occurred in 10 915 (24%) patients. Average age was 54.3±9.6 years, 52% were men, 17% had cardiovascular disease, and 10% chronic kidney disease. Compared with other angiotensin receptor blockers, the adjusted hazard for olmesartan was 0.99 (95% confidence interval, 0.94-1.05) for all-cause hospitalization and mortality; 0.90 (0.62-1.30) for all-cause mortality; 0.99 (0.94-1.05) for all-cause hospital admission; 0.88 (0.78-1.00) for cardiovascular disease-related admission, and 1.09 (0.98-1.20) for gastrointestinal disease-related hospitalization in the overall cohort. Olmesartan use was associated with an adjusted hazard for the primary outcome of 1.11 (0.99-1.24) in subjects with history of cardiovascular disease and 1.21 (1.04-1.41) in subjects with chronic kidney disease. In conclusion, there is no robust signal for harm with olmesartan use. Risk may be increased in kidney disease; thus, given the widespread availability of alternate agents, olmesartan should be used with caution in this subgroup pending further study.
- Hypertension.Hypertension.2014 May;63(5):977-83. doi: 10.1161/HYPERTENSIONAHA.113.02855. Epub 2014 Feb 17.
- Olmesartan has been linked with increased risk of cardiovascular mortality and sprue-like enteropathy. We compared outcomes between olmesartan and other angiotensin receptor blockers in a large clinical registry of patients with diabetes mellitus. A retrospective cohort analysis using nationwide US-
- PMID 24535009
- Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
- Ismaila A1, Corriveau D, Vaillancourt J, Parsons D, Dalal A, Su Z, Sampalis JS.Author information 1Medical Affairs, GlaxoSmithKline , Mississauga, ON , Canada.AbstractAbstract Objective: Poor adherence to treatment may contribute to the treatment gap in chronic obstructive pulmonary diseases (COPD). The aim of the current study was to describe the association between adherence to treatment and the risk of COPD moderate (ME) and severe (SE) exacerbations, and health care utilization. Research design and methods: Observational single cohort study utilizing the Quebec Provincial Health Insurance databases. All patients older than 40 years with a diagnosis of COPD between 2001 and 2010 were entered in the study cohort at the time of their first prescription for tiotropium (TIO) alone or co-administered with fluticasone propionate/salmeterol (TIO + FSC). Follow-up continued to the last known claim or death. Adherence was measured by the medication possession ratio (MPR) ≥80% and persistence defined as no treatment gap ≥30 days. Main outcome measures: ME was defined as use of an oral corticosteroid or antibiotic, SE as COPD related hospitalization or an emergency room (ER) visit. COPD related health care resource utilization ascertained was prescription of rescue medications, ER visits, hospitalizations, intensive care unit (ICU) admissions, intubations, and general practitioner (GP) and respirologist visits. Results: There were 23,707 patients included in this study. Compliance and persistence with TIO for monotherapy patients were 61.1% and 47.6% respectively. For patients treated with TIO + FSC, compliance and persistence for TIO were 62.9% and 45.3% respectively, and for FSC they were 35.4% and 33.0%. Multivariate analyses showed a significant (P < 0.001) adjusted odds ratios for ME (ORME) and SE (ORSE) for TIO compliant vs. non-compliant patients (TIO: ORME = 0.543, ORSE = 0.712; TIO + FSC: ORME = 0.436, ORSE = 0.570). Similarly for FSC compliance: ORME = 0.546; ORSE = 0.749. Similar results were observed for persistence. Compliance and persistence with TIO and FSC were associated with significantly reduced rates of health care utilization. Conclusions: Despite the typical limitations of an administrative database study, the results of this large population-based study have shown that reduced adherence to treatment with TIO and FSC is associated with increased risk for exacerbations and higher health care utilization in COPD patients.
- Current medical research and opinion.Curr Med Res Opin.2014 Apr 14. [Epub ahead of print]
- Abstract Objective: Poor adherence to treatment may contribute to the treatment gap in chronic obstructive pulmonary diseases (COPD). The aim of the current study was to describe the association between adherence to treatment and the risk of COPD moderate (ME) and severe (SE) exacerbations, and heal
- PMID 24666181
- Impact of adherence to treatment with fluticasone propionate/salmeterol in asthma patients.
- Ismaila A1, Corriveau D, Vaillancourt J, Parsons D, Stanford R, Su Z, Sampalis JS.Author information 1Medical Affairs, GlaxoSmithKline , Mississauga, ON , Canada.AbstractAbstract Objective: Low adherence with asthma treatment may be associated with suboptimal outcomes and hence create a treatment gap in the real-life setting. The objective of this study was to assess the long-term association between adherence to treatment with fixed-dose fluticasone propionate/salmeterol (FSC) and the risk of exacerbations and health care utilization in patients with asthma. Research design and methods: Observational single cohort study utilizing the Quebec Health Insurance databases. All patients (age >12 years) with a diagnosis of asthma (ICD9-CM 493.xx) between 2001 and 2010 were entered into the study cohort at the time of their first prescription for FSC at any dose. Follow-up continued to the last known claim or death. Adherence to treatment was ascertained as compliance (medication possession ratio ≥80%) and persistence (absence of treatment gap ≥30 days). Main outcome measures: Outcomes assessed were exacerbations defined as one of the following: use of oral corticosteroid (OCS), emergency room (ER) visit for asthma or hospitalization for asthma. Asthma related health care resource utilizations ascertained were number of prescription claims for rescue medications, ER visits, hospitalizations, intensive care unit (ICU) stay, intubations, and general practitioner (GP) and respirologist visits. Results: A total of 19,126 patients were included in the study. The proportion of compliant and persistent patients were 42.7% and 29.3% respectively. Multivariate logistic regression analyses showed a significantly reduced adjusted odds of exacerbations for compliant (OR = 0.48; 95% CI: 0.44-0.54) and persistent patients (OR = 0.42; 95% CI: 0.38-0.48). Similarly, significantly lower rates of health care utilization were observed for compliant and persistent patients. Conclusions: The results of this large population-based study have shown that increased adherence to treatment with FSC is associated with lower risk for exacerbations, lower rescue medication use and lower health care utilization in asthma patients. Despite the typical limitations of an administrative database study including validity of the diagnosis, the fact that compliance and persistence are calculated based on filled claims which does not guarantee that the patients actually took their medications, and the absence of clinical and laboratory data, the findings have implications for physician and patient awareness of the importance of adherence in the management of asthma.
- Current medical research and opinion.Curr Med Res Opin.2014 Apr 14. [Epub ahead of print]
- Abstract Objective: Low adherence with asthma treatment may be associated with suboptimal outcomes and hence create a treatment gap in the real-life setting. The objective of this study was to assess the long-term association between adherence to treatment with fixed-dose fluticasone propionate/salm
- PMID 24666139
Japanese Journal
- Analysis of variation in length of stay (LOS) after ischemic and hemorrhagic stroke using the Charlson Comorbidity Index (CCI)
- ,
- Journal of Physical Therapy Science 27(3), 799-803, 2015
- … [Results] Independent variables with significant relationships with the log-transformed length of stay included gender, type of insurance, the size of city of residence, the number of beds in the hospital, the location of the medical institution, hospitalization path, receipt of physical therapy, treatment involving brain surgery, death, the type of stroke, and CCI. …
- NAID 130005061661
- Diagnosis Procedure Combination制度の機能評価係数IIに影響を与える要因
- 中島 尚登,矢野 耕也,長澤 薫子 [他],小林 英史,横田 邦信
- 日本衛生学雑誌 70(1), 40-53, 2015
- … Group I hospitals showed the highest bed capacity, and numbers of hospitalization days, operations, chemotherapies, radiotherapies and general anesthesia procedures. … In group II hospitals, function evaluation coefficient II significantly correlated to bed capacity, the numbers of ambulance conveyances, hospitalization days, operations, general anesthesia procedures, and mean hospitalization days. …
- NAID 130004776111
- 働き盛り世代の男性における8年間の追跡からみた年代別虚血性心疾患の発症リスク
- 畑中 陽子,玉腰 暁子,津下 一代
- 産業衛生学雑誌 advpub(0), 2015
- 目的:在職中の虚血性心疾患の発症を防ぐため,そのリスクを年齢群別に検討することを目的に,8年間の診療報酬明細書(レセプト)データに基づき,デンソー健康保険組合に加入する男性従業員を追跡したので報告する.対象と方法:2003年時点で30歳から55歳である男性従業員27,945人のうち,2003年の定期健診データが存在する19,742人(70.6%)について,レセプトデータの入院歴と資格喪失データから …
- NAID 130004743877
Related Links
- hospitalization insuranceとは。意味や和訳。入院(費)保険,病院費用保険. - 80万項目以上収録、例文・コロケーションが豊富な無料英和和英辞典。 ... 入院(費)保険,病院費用保険. 出典:ランダムハウス英和大辞典
- With hospitalization insurance coverage, you can focus on getting better and on the additional expenses that are adding up ... What is Hospitalization Insurance? TD Coverage for Accident and Sickness Hospitalization (TD CASH ...
★リンクテーブル★
[★]
- 関
- admission、admit、hospitalisation、hospitalize、institutionalized